AptarGroup Inc. presented an overview of its financial performance and business segments at the J.P. Morgan Healthcare Conference. The company reported $3.6 billion in total annual revenue for 2024, with 46% of sales from its Beauty segment and 33% from Pharma. Aptar Pharma, a subsidiary, generated $1.6 billion in revenue, with a diversified portfolio across proprietary drug delivery systems, injectable solutions, and active material science solutions. The company highlighted its position as a leader in precision drug dosing and dispensing, serving highly regulated markets and leveraging integrated labs and prototyping for efficient solution design. AptarGroup also outlined its market presence across Beauty, Pharma, Closures, Beverage, Home Care, Food, and Personal Care, and emphasized a balanced approach to investments and long-term growth. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.